›› 2018, Vol. 38 ›› Issue (1): 52-.doi: 10.3969/j.issn.1674-8115.2018.01.009

• Original article (Clinical research) • Previous Articles     Next Articles

Expression of MTA2 in endometrial carcinomas and its correlation with clinicopathological features

GAO Ling-tong, LIU Wei   

  1. Pathology Center, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai 200080, China
  • Online:2018-01-28 Published:2018-03-09
  • Supported by:
    National Natural Science Foundation of China，81302253；Program of Shanghai Municipal Commission of Health and Family Planning，20124y081

PDF (PC)

1123

Abstract: Objective · To explore the expression of MTA2 in endometrial carcinomas and its correlation with clinicopathological features.
Methods · The GCBI database was used to analyse the MTA2 expression in most cancers. Immunohistochemical staining of MTA2, p53, ER, PR and Ki-
67 was performed in 119 endometrial carcinomas tissues and 21 corresponding adjacent non-neoplastic endometria. And the correlation between MTA2
expression and clinicopathological characteristics was evaluated as well as the correlation between MTA2 expression and the expression of ER, PR, p53
or Ki-67. Results · The expression of MTA2 was up-regulated in most of the tumors including endometrial carcinomas in GCBI database. MTA2 was
overexpressed in endometrial carcinoma compared with the adjacent normal tissues (P=0.000)，and the expression level was related to tumor grade
（χ2=8.072, P=0.018） and Ki-67 expression (r=0.227, P=0.013). Conclusion · MTA2 may act as an oncogene in endometrial carcinomas, and it is a promising target for diagnosis and treatment of endometrial carcinomas.

Key words: endometrial carcinomas, MTA2, expression, tumor grade, Ki-67